Simponi Aria® (golimumab)

Simponi Aria (golimumab) is covered only for its FDA‑approved indications — adult rheumatoid arthritis, psoriatic arthritis, adult ankylosing spondylitis, and polyarticular/juvenile spondyloarthropathy forms of juvenile idiopathic arthritis — and non‑FDA uses are excluded. Coverage requires age limits (≥18 for adults, ≥2 for JIA), appropriate prescriber specialty (usually rheumatologist; rheumatologist or dermatologist for PsA), adherence to recommended IV dosing (adult 2 mg/kg IV at weeks 0 and 4 then q8w; pediatric 80 mg/m² same schedule), required prior therapy trials (e.g., RA: 3‑month trial of another biologic or a conventional DMARD), initial authorization for 6 months (renewal 12 months), and reauthorization documentation of ≥6 months on therapy with objective or symptomatic improvement.

"Adult patients with moderately to severely active rheumatoid arthritis"